Company: SNY
Filing Date: 2025-10-29
Form Type: 424B5
Source: 0001193125-25-255563
Chunk: 84

Company: Sanofi
Filing Date: 2025-10-29
Form: 424B5
Chunk 84
---
 de plan de sauvegarde) or a draft judicial reorganization plan ( projet de plan de redressement) with respect to Sanofi S.A. which:

| • |     | would have to take into account any known subordination/intercreditor agreements entered into by the creditors 
 prior to the opening of the proceedings (as the case may be); and                                              |

| • |     | could in particular provide for a rescheduling and/or a partial or full                                                    
 write-off of the amount due under the debt securities and/or debt-to-equity swaps and/or the sale of part of the business. |

Should the plan be approved by each class and provided certain requirements are met, the plan would be imposed upon the dissenting creditors of each class. Should the plan be rejected by one or more classes, the French court may nevertheless adopt it and impose it upon the dissenting creditors and classes, provided certain requirements are met. In addition, assuming that no restructuring plan is approved by the relevant court or that the debtor’s recovery is clearly impossible, the relevant court would open judicial liquidation proceedings. Practically, it is highly unlikely that the holders of debt securities, as unsecured creditors, could be repaid of their claims in full within that context. Therefore, certain provisions of the indenture may not be enforced or enforceable by the trustee or holders of debt securities issued under this prospectus in such cases. Moreover, the commencement of insolvency proceedings against Sanofi S.A. would have a material adverse effect on the market value of the debt securities. As a consequence, any decisions taken by a class of affected parties could negatively and significantly impact the holders of debt securities and cause them to lose all or part of their investment, should they not be able to recover all or part of the amounts due to them from Sanofi S.A. You may be unable to recover in civil proceedings for U.S. securities laws violations. Sanofi is a limited liability company ( société anonyme) organized under the laws of France, and most of our officers and directors reside outside the United States. In addition, a substantial portion of our assets is located in France. Accordingly, it may be difficult for investors to obtain jurisdiction over us, our non-U.S.resident officers and directors in courts in the United States, or obtain evidence in France or from any French citizen or any individual being resident in France or any officer, representative, agent or employee of a legal person having its registered office or an establishment in a territory of France, in connection